Levilimab
Based on 1 Customer Validation
Levilimab (BCD-089) is an IL-6 receptor blocker that binds to both membrane-bound and soluble IL-6Rα. Levilimab inhibits IL-6 signaling, including classical signaling and trans-signaling, by blocking IL-6 binding. Levilimab can be used in research on rheumatoid arthritis and COVID-19.
For research use only. We do not sell to patients.
- Purity : 97.52%
- CAS No.: 2035008-70-7
- Molecular Weight:145.7 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
IL-6 |
In Vitro
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IL-6R alpha Protein, Human (CHO, HY-P7223) can bind Levilimab. The EC50 for this effect is 24.18 ng/mL.
Product Details
-
CAS No. 2035008-70-7
-
Accession P08887
-
Synonyms BCD-089
-
Molecular Weight 145.7 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
97.52%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)